Raymond James Trust N.A. decreased its stake in Gilead Sciences (NASDAQ:GILD) by 14.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,593 shares of the biopharmaceutical company’s stock after selling 3,798 shares during the quarter. Raymond James Trust N.A.’s holdings in Gilead Sciences were worth $1,618,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of the business. FMR LLC grew its stake in Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares during the period. Macquarie Group Ltd. grew its stake in Gilead Sciences by 26.6% in the third quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after acquiring an additional 100,741 shares during the period. Vanguard Group Inc. grew its stake in Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares during the period. Northern Trust Corp grew its stake in Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after acquiring an additional 116,780 shares during the period. Finally, Toronto Dominion Bank boosted its position in shares of Gilead Sciences by 19.0% during the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock worth $33,445,000 after buying an additional 75,364 shares during the period. Hedge funds and other institutional investors own 77.91% of the company’s stock.
In other news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $73.14, for a total value of $3,657,000.00. Following the transaction, the director now owns 3,067,762 shares in the company, valued at approximately $224,376,112.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director John Francis Cogan sold 5,833 shares of the business’s stock in a transaction that occurred on Friday, March 23rd. The stock was sold at an average price of $75.02, for a total value of $437,591.66. Following the completion of the transaction, the director now owns 58,452 shares in the company, valued at approximately $4,385,069.04. The disclosure for this sale can be found here. Insiders have sold a total of 426,934 shares of company stock valued at $33,847,101 in the last quarter. Company insiders own 1.30% of the company’s stock.
Several research firms have recently weighed in on GILD. Vetr cut Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 price objective for the company. in a research report on Monday, January 29th. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their price target for the company from $88.80 to $76.00 in a research report on Tuesday, January 30th. Morgan Stanley reduced their price target on Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 7th. Bank of America upped their price objective on Gilead Sciences from $82.00 to $87.00 and gave the company a “neutral” rating in a research note on Wednesday, February 7th. Finally, BMO Capital Markets upped their price objective on Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a research note on Thursday, February 8th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and an average target price of $88.61.
Gilead Sciences stock traded down $1.41 during midday trading on Friday, reaching $73.41. The stock had a trading volume of 6,439,529 shares, compared to its average volume of 6,802,121. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $89.54. The firm has a market capitalization of $95,715.63, a price-to-earnings ratio of 8.58, a PEG ratio of -1.69 and a beta of 1.19. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s revenue was down 18.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.70 EPS. sell-side analysts expect that Gilead Sciences will post 6.21 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Shareholders of record on Friday, March 16th were paid a dividend of $0.57 per share. The ex-dividend date was Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 3.11%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is 26.64%.
WARNING: “Raymond James Trust N.A. Has $1.62 Million Holdings in Gilead Sciences (GILD)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/raymond-james-trust-n-a-has-1-62-million-position-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.